Cryptic resolution sites in the vector plasmid lead to the heterogeneities in the rAAV vectors
- 3 January 2023
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (1) , e28433
Abstract
Recombinant adeno‐associated virus (rAAV) vectors carry a cassette of interest retaining only the inverted terminal repeats (ITRs) from the wild‐type virus. Conventional rAAV production primarily uses a vector plasmid as well as helper genes essential for AAV replication and packaging. Nevertheless, plasmid backbone related contaminants have been a major source of vector heterogeneity. The mechanism driving the contamination phenomenon has yet to be elucidated. Here we identified cryptic resolution sites in the plasmid backbone as a key source for producing snapback genomes, which leads to the increase of vector genome heterogeneity in encapsidated virions. By using a single ITR plasmid as a model molecule and mapping subgenomic particles, we found that there exist a few typical DNA break hotspots in the vector DNA plasmid backbone, for example, on the ampicillin DNA element, called aberrant rescue sites. DNA around these specific breakage sites may assume some typical secondary structures. Similar to normal AAV vectors, plasmid DNA with a single ITR was able to rescue and replicate efficiently. These subgenomic DNA species significantly compete for trans factors required for rAAV rescue, replication, and packaging. The replication of single ITR contaminants during AAV production is independent of size. Packaging of these species is greatly affected by its size. A single ITR and a cryptic resolution site in the plasmid work synergistically, likely causing a source of plasmid backbone contamination.Keywords
Funding Information
- National Institutes of Health
This publication has 19 references indexed in Scilit:
- DNA Minicircle Technology Improves Purity of Adeno-associated Viral Vector PreparationsMolecular Therapy Nucleic Acids, 2016
- Novel synthetic plasmid and Doggybone™ DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in miceHuman Vaccines & Immunotherapeutics, 2015
- Advanced Characterization of DNA Molecules in rAAV Vector Preparations by Single-stranded Virus Next-generation SequencingMolecular Therapy Nucleic Acids, 2015
- Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk AssessmentBiomedicines, 2014
- The Extragenic Spacer Length Between the 5′ and 3′ Ends of the Transgene Expression Cassette Affects Transgene Silencing From Plasmid-based VectorsMolecular Therapy, 2012
- Undetectable Transcription of cap in a Clinical AAV Vector: Implications for Preformed Capsid in Immune ResponsesMolecular Therapy, 2009
- Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno-Associated Virus Production and Their in Vivo Persistence after Vector DeliveryMolecular Therapy, 2005
- Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivoGene Therapy, 2004
- Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivoGene Therapy, 2003
- Rescue of adeno-associated virus from recombinant plasmids: Gene correction within the terminal repeats of AAVCell, 1983